Hematologic Oncology Articles | Page 3

Combined Radiation Therapy and Checkpoint Inhibition in Lymphoma: A Case Report and Brief Review
The emergence of immune checkpoint inhibitors as an effective treatment strategy is a result of increased understanding of the elaborate relationship between tumor cells, their microenvironment and the host immune response.
Findings from a small, retrospective study showed that external beam radiation therapy induced an overall response rate of 86% in patients with relapsed/refractory follicular lymphoma.
FDA Approves Blinatumomab for MRD+ ALL
The FDA has approved blinatumomab for the treatment of patients with minimal residual disease–positive B-cell precursor acute lymphoblastic leukemia.
Ponatinib Maintains Benefit in Chronic-Phase CML at 5 Years
Ponatinib maintained deep, durable responses in heavily pretreated patients with chronic-phase chronic myeloid leukemia (CP-CML).
Venetoclax/Rituximab Positive PFS Data Published in NEJM
The regimen of venetoclax (Venclexta) plus rituximab (Rituxan) lowered the risk of disease progression or death by 83% versus bendamustine (Treanda) plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia.
Goy Lends Insight on Acalabrutinib and Ibrutinib in MCL
Andre Goy, MD, discusses the excitement surrounding acalabrutinib, as well as emerging ibrutinib combination strategies for the treatment of patients with mantle cell lymphoma.
CLL Expert Explains Latest Treatment Developments in the Field
Neil E. Kay, MD, discusses the available options and sequencing challenges for patients with relapsed/refractory chronic lymphocytic leukemia, as well as next steps for advancing outcomes for this patient population.
FDA Approves Brentuximab Vedotin for Frontline Hodgkin Lymphoma
The FDA has approved brentuximab vedotin for use in combination with chemotherapy as a frontline treatment for adult patients with stage III or IV classical Hodgkin lymphoma.
Ibrutinib, Venetoclax, and Obinutuzumab Triplet Safe, Effective as Initial CLL Therapy
Kerry A. Rogers, MD, discusses the promise of the obinutuzumab, ibrutinib, and venetoclax triplet as a first-line treatment for patients with chronic lymphocytic leukemia.
Fostamatinib Active in Chronic Immune Thrombocytopenic Purpura
Fostamatinib resulted in clinically meaningful, ongoing platelet responses and a low rate of bleeding events in 43% of patients with chronic immune thrombocytopenic purpura with long-disease duration. 
Publication Bottom Border
Border Publication